INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)
INcentives and ReMINDers to Improve Long-term Medication Adherence
RAND
550 participants
Apr 2, 2025
INTERVENTIONAL
Conditions
Summary
Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, Randomized Trial (SMART) design in one of the largest HIV clinics in Uganda to identify the most cost-effective adaptive intervention that if found effective is generalizable to other settings and other chronic diseases.
Eligibility
Inclusion Criteria6
- Male and female clients age 18 and older.
- Started ART at Mildmay or another clinic within the preceding 2 months
- Able to speak and understand either English or Luganda.
- Have their own cell phone or have consistent access to someone else's phone.
- Willing to receive daily text messages for the 6 months of intervention duration.
- Willing and able to use the WisePill device distributed for adherence verification for the duration of the study.
Exclusion Criteria3
- Not mentally fit to consent.
- Language other than Luganda or English.
- Not willing to consistently use the Wisepill device for adherence measurement.
Interventions
Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.
Participants will be eligible to (draw a prize in monthly prize group) or get a monthly prize (monthly escalated group) if they take their medication within +/-one hour of the stated existing routine to which pill-taking is anchored on at least 80% of days for 3-months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06949774